Johnson & Johnson (NYSE: JNJ) announces it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine. With this acquisition, Johnson & Johnson adds CAPLYTA® (lumateperone) to its robust portfolio of differentiated medicines. CAPLYTA® is a once-daily oral therapy approved to treat adults with schizophrenia, as well as the first and only U.S. Food and Drug Administration (FDA)-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
Read the full article: Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership //
Source: https://www.businesswire.com/news/home/20250402861736/en/Johnson-Johnson-Closes-Landmark-Intra-Cellular-Therapies-Inc.-Acquisition-to-Solidify-Neuroscience-Leadership